Literature DB >> 18972444

Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.

Yan-Dong Wang1, Wei-Dong Chen, Meihua Wang, Donna Yu, Barry M Forman, Wendong Huang.   

Abstract

The farnesoid X receptor (FXR) is a nuclear receptor that plays key roles in hepatoprotection by maintaining the homeostasis of liver metabolism. FXR null mice display strong hepatic inflammation and develop spontaneous liver tumors. In this report, we demonstrate that FXR is a negative modulator of nuclear factor kappaB (NF-kappaB)-mediated hepatic inflammation. Activation of FXR by its agonist ligands inhibited the expression of inflammatory mediators in response to NF-kappaB activation in both HepG2 cells and primary hepatocytes cultured in vitro. In vivo, compared with wild-type controls, FXR(-/-) mice displayed elevated messenger RNA (mRNA) levels of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), interferon-inducible protein 10, and interferon-gamma in response to lipopolysaccharide (LPS). Examination of FXR(-/-) livers showed massive necroses and inflammation after treatment with LPS at a dose that does not induce significant liver damage or inflammation in wild-type mice. Moreover, transfection of a constitutively active FXR expression construct repressed the iNOS, COX-2, interferon-inducible protein 10 and interferon-gamma mRNA levels induced by LPS administration. FXR activation had no negative effects on NF-kappaB-activated antiapoptotic genes, suggesting that FXR selectively inhibits the NF-kappaB-mediated hepatic inflammatory response but maintains or even enhances the cell survival response. On the other hand, NF-kappaB activation suppressed FXR-mediated gene expression both in vitro and in vivo, indicating a negative crosstalk between the FXR and NF-kappaB signaling pathways. Our findings reveal that FXR is a negative mediator of hepatic inflammation, which may contribute to the critical roles of FXR in hepatoprotection and suppression of hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972444      PMCID: PMC3056574          DOI: 10.1002/hep.22519

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  48 in total

Review 1.  The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function.

Authors:  M Ricote; J T Huang; J S Welch; C K Glass
Journal:  J Leukoc Biol       Date:  1999-11       Impact factor: 4.962

Review 2.  Cross-talk between glucocorticoid receptor and AP-1.

Authors:  P Herrlich
Journal:  Oncogene       Date:  2001-04-30       Impact factor: 9.867

3.  The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression.

Authors:  N L Urizar; D H Dowhan; D D Moore
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

4.  The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain.

Authors:  R M Nissen; K R Yamamoto
Journal:  Genes Dev       Date:  2000-09-15       Impact factor: 11.361

5.  Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide.

Authors:  S Ke; A B Rabson; J F Germino; M A Gallo; Y Tian
Journal:  J Biol Chem       Date:  2001-07-24       Impact factor: 5.157

6.  Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis.

Authors:  L Qiao; E Studer; K Leach; R McKinstry; S Gupta; R Decker; R Kukreja; K Valerie; P Nagarkatti; W El Deiry; J Molkentin; R Schmidt-Ullrich; P B Fisher; S Grant; P B Hylemon; P Dent
Journal:  Mol Biol Cell       Date:  2001-09       Impact factor: 4.138

Review 7.  AP-1--glucocorticoid receptor crosstalk taken to a higher level.

Authors:  M Karin; L Chang
Journal:  J Endocrinol       Date:  2001-06       Impact factor: 4.286

8.  Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450.

Authors:  E G Schuetz; S Strom; K Yasuda; V Lecureur; M Assem; C Brimer; J Lamba; R B Kim; V Ramachandran; B J Komoroski; R Venkataramanan; H Cai; C J Sinal; F J Gonzalez; J D Schuetz
Journal:  J Biol Chem       Date:  2001-08-16       Impact factor: 5.157

9.  Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis.

Authors:  J H Baek; J E Jang; C M Kang; H Y Chung; N D Kim; K W Kim
Journal:  Oncogene       Date:  2000-09-21       Impact factor: 9.867

10.  Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.

Authors:  C J Sinal; M Tohkin; M Miyata; J M Ward; G Lambert; F J Gonzalez
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

View more
  216 in total

1.  A novel heterozygous NR1H4 termination codon mutation in idiopathic infantile cholestasis.

Authors:  Xiu-Qi Chen; Lin-Lin Wang; Qing-Wen Shan; Qing Tang; Ya-Nan Deng; Shu-Jun Lian; Xiang Yun
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

2.  Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice.

Authors:  Zhipeng Meng; Xiaoqiong Wang; Yichao Gan; Yunfeng Zhang; Hong Zhou; Carl Van Ness; Jun Wu; Guiyu Lou; Hua Yu; Chao He; Rongzhen Xu; Wendong Huang
Journal:  J Hepatol       Date:  2012-06-21       Impact factor: 25.083

3.  Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice.

Authors:  Jiyoung Lee; Sunmi Seok; Pengfei Yu; Kyungsu Kim; Zachary Smith; Marcelo Rivas-Astroza; Sheng Zhong; Jongsook Kim Kemper
Journal:  Hepatology       Date:  2012-04-24       Impact factor: 17.425

Review 4.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

5.  FXR deletion in hepatocytes does not affect the severity of alcoholic liver disease in mice.

Authors:  Min Zhang; Bo Kong; Mingxing Huang; Ruixuan Wan; Laura E Armstrong; Justin D Schumacher; Daniel Rizzolo; Monica D Chow; Yi-Horng Lee; Grace L Guo
Journal:  Dig Liver Dis       Date:  2018-04-23       Impact factor: 4.088

6.  Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation.

Authors:  Eun Sun Jang; Jung-Hwan Yoon; Sung-Hee Lee; Soo-Mi Lee; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-27       Impact factor: 4.553

7.  Altered zinc balance in the Atp7b-/- mouse reveals a mechanism of copper toxicity in Wilson disease.

Authors:  Kelsey A Meacham; María Paz Cortés; Eve M Wiggins; Alejandro Maass; Mauricio Latorre; Martina Ralle; Jason L Burkhead
Journal:  Metallomics       Date:  2018-11-14       Impact factor: 4.526

8.  Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Cunbao Li; Cong Guo; Yanyan Li; Hui Qi; Hailing Shen; Jing Kong; Xuecheng Long; Frank Yuan; Xichun Wang; Wendong Huang
Journal:  Mol Endocrinol       Date:  2014-12-12

9.  Mechanisms of STAT3 activation in the liver of FXR knockout mice.

Authors:  Guodong Li; Yan Zhu; Ossama Tawfik; Bo Kong; Jessica A Williams; Le Zhan; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-03       Impact factor: 4.052

10.  A Novel Combination of Fruits and Vegetables Prevents Diet-Induced Hepatic Steatosis and Metabolic Dysfunction in Mice.

Authors:  Weimin Guo; Dayong Wu; Maria C Dao; Lijun Li; Erin D Lewis; Edwin F Ortega; Heesun Eom; Michael Thomas; Mariana Nikolova-Karakashian; Mohsen Meydani; Simin N Meydani
Journal:  J Nutr       Date:  2020-11-19       Impact factor: 4.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.